Axpero 5 Mg (Axitinib)
Price range: 78.00$ through 176.00$
Product Overview Axipero 5 Mg, produced by Intas Pharmaceuticals Ltd, is an oral tyrosine kinase inhibitor formulated for the treatment of advanced renal cell carcinoma (RCC). The product arrives in a strip containing 14 tablets, each strength 5 Mg.
| Active Ingredients | Axitinib |
|---|---|
| Delivery Time | 6 To 15 days |
| Indication | Kidney cancer |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packaging | 14 Tablets in Strip |
| Strength | 5 mg |
Product Overview
Axipero 5 Mg, produced by Intas Pharmaceuticals Ltd, is an oral tyrosine kinase inhibitor formulated for the treatment of advanced renal cell carcinoma (RCC). The product arrives in a strip containing 14 tablets, each strength 5 Mg. Additional pack sizes of 28, 56, and 84 tablets allow clinicians to match supply with patient‑specific treatment plans. The medication is classified under kidney care and meets the regulatory standards of the US FDA for oncology drugs. All batches are manufactured under Good Manufacturing Practice (GMP) conditions and are subject to rigorous quality control, ensuring consistent potency and purity. The tablets are film‑coated to protect the active ingredient from moisture, and each strip includes a patient information leaflet that outlines storage instructions and handling precautions.
What is Axipero 5 Mg (Axitinib)?
Axipero contains axitinib, a highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. By binding to these receptors, axitinib reduces the signaling pathways that drive new blood‑vessel formation inside tumors. This anti‑angiogenic action helps to limit tumor growth and metastasis in patients with RCC. The drug is recognized in the NIH database of targeted cancer therapies and is listed on Drugs.com as an approved kidney‑cancer medication. Clinical studies have shown that axitinib can achieve objective response rates of 30‑40 % in pre‑treated patients, and many subjects experience a delay in disease progression measured by RECIST criteria. Pharmacodynamically, the inhibition of VEGFR signaling leads to reduced micro‑vascular density, which translates into decreased nutrient supply for the tumor.
Uses and Benefits
Clinically, Axipero is employed as a second‑line therapy for patients whose disease has progressed after treatment with another VEGF‑targeted agent. In pivotal trials, axitinib demonstrated a statistically significant improvement in progression‑free survival compared with placebo, and many patients experienced fewer dose reductions due to hypertension or liver enzyme abnormalities. The oral route provides convenience, and the consistent dosing schedule supports adherence. Real‑world data suggest that patients often maintain a good quality of life while on therapy, especially when blood pressure is carefully monitored. Moreover, some analyses have indicated a modest benefit in overall survival when axitinib is used earlier in the treatment pathway, reinforcing its role as a valuable option for disease control.
How It Works
Axipero works by competitively inhibiting the ATP‑binding site of VEGFR‑1, VEGFR‑2, and VEGFR‑3 on endothelial cells. This blockade prevents ligand‑induced receptor activation, leading to reduced endothelial proliferation and migration. Consequently, micro‑vascular density within the tumor microenvironment declines, starving cancer cells of oxygen and nutrients. The inhibition is dose‑dependent, and continuous exposure is required to sustain the anti‑angiogenic response. Pharmacokinetic studies show that axitinib reaches steady‑state plasma concentrations within approximately 7 days of twice‑daily dosing, has a half‑life of about 17 hours, and is primarily metabolized by CYP3A4 and CYP2C9 enzymes before renal excretion of metabolites.
Dosage Guidelines
The recommended initial dose of axitinib is 5 Mg taken orally twice daily, with or without food, as indicated in the product label. Physicians may adjust the dose upward to 10 Mg twice daily or reduce it to 2 Mg twice daily based on tolerability, renal function, or concurrent medications. Patients should undergo routine laboratory monitoring, including liver function tests, serum creatinine, and blood pressure checks, to guide dose modifications. In subjects with moderate hepatic impairment, the maximum recommended dose is 2 Mg twice daily, while those with severe impairment should not exceed 1 Mg twice daily. Dose interruptions are advised for Grade 3 or 4 toxicities, and resumption occurs at a reduced dose once toxicity resolves.
Side Effects
The most frequently reported adverse events include hypertension, diarrhea, fatigue, nausea, and elevated liver enzymes. While many of these reactions are mild to moderate, some patients may experience serious complications such as arterial occlusion, severe hepatic injury, or gastrointestinal bleeding. Prompt reporting of new symptoms is crucial, and clinicians often manage hypertension with antihypertensive agents or adjust the axitinib dose when laboratory abnormalities arise. Supportive care measures, including hydration, anti‑emetics, and periodic blood pressure monitoring, can improve patient comfort during treatment. Rare but potentially life‑threatening events such as posterior reversible encephalopathy syndrome (PRES) and severe cardiac ischemia have been reported; see the FDA safety information for detailed guidance.
Warnings and Precautions
Axipero is contraindicated in individuals with uncontrolled hypertension, recent myocardial infarction, or known hypersensitivity to axitinib. Caution is advised for patients with a history of cardiac ischemia, coagulopathy, or significant hepatic impairment, as these conditions may amplify drug‑related risk. Concomitant use of strong CYP3A4 inhibitors can increase axitinib exposure and should be avoided unless dose reduction is planned. Pregnant women should not use the medication, and effective contraception is required for both men and women of reproductive potential throughout therapy. The FDA labeling provides detailed contraindication and precaution information.
Manufacturer and Packaging
Axipero is manufactured by Intas Pharmaceuticals Ltd, a GMP‑certified company with a track record in oncology formulation. Each strip contains 14 tablets of 5 Mg, and the product is sealed in moisture‑resistant blister packs. Available pack sizes include 28, 56, and 84 tablets, allowing flexibility for clinic‑based dosing schedules. Shipping is typically processed within one business day, with estimated delivery windows of 6 to 15 days depending on the destination. Customers receive tracking information and can contact the pharmacy’s licensed pharmacists for any questions regarding storage or administration. All personal data are handled in compliance with applicable privacy regulations, and secure checkout options protect payment information.
Frequently Asked Questions
Q: What is the indication for Axipero 5 Mg? A: Axipero is indicated for the treatment of advanced renal cell carcinoma in adult patients who have progressed after prior VEGF‑targeted therapy.
Q: How should I store the medication? A: Store the tablets at room temperature, away from moisture and heat. Keep the strip sealed until ready to use, and discard any tablets that become discolored or damaged.
Q: Can I take Axipero with food? A: Axipero may be taken with or without food. However, taking it with a consistent meal each time can help maintain steady drug levels.
Q: What should I do if I miss a dose? A: If you miss a dose, take it as soon as you remember. If it is near the time of the next scheduled dose, skip the missed dose and resume your regular schedule; do not double the dose.
Q: Are there any drug interactions I should be aware of? A: Patients should inform their healthcare provider about all medications, supplements, and herbal products, especially strong CYP3A4 inhibitors or inducers, as these can alter axitinib exposure and efficacy.
Related Products
- Potassium Citrate 5 mg (Generic)
- Relgin 0.5 mg (Rasagiline)
- Glycolate 1 mg Tablet (Glycopyrrolate)
- Morr-F 3 (Minoxidil/Finasteride)
- Adapen Gel (Adapalene)
- Intacaine 2% Gel 30g (Lidocaine)
- Acamptas 333 mg (Acamprosate)
- Naltima 50 mg (Naltrexone)
- Itaspor 100 mg (Itraconazole)
- C-NAC Eye Drop (Sodium Carboxymethylcellulose/N-Acetyl-Carnosine)
- Lashisma Solution 3 ml (Bimatoprost)
- Cyclogyl Eye Drop (Cyclopentolate)
Related Products
Product Overview Fosbait 250 mg is a prescription phosphate binder for adult patients with chronic kidney disease (CKD) on dialysis. The active ingredient lanthanum carbonate is formulated as a tablet taken with meals to bind dietary phosphorus. Pana
In stock
In stock
Reviews
There are no reviews yet.